ANTH (Anthera Pharmaceuticals) EBITDA Margin %: 0.00% (As of Mar. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Anthera Pharmaceuticals EBITDA Margin %?

Anthera Pharmaceuticals ANTH EBITDA Margin % is 0.00% as of Mar. 2018.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Anthera Pharmaceuticals's EBITDA for the three months ended in Mar. 2018 was $-10.81 Mil. Anthera Pharmaceuticals's Revenue for the three months ended in Mar. 2018 was $0.00 Mil. Therefore, Anthera Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2018 was 0.00%.

Anthera Pharmaceuticals  (OTCPK:ANTH) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Anthera Pharmaceuticals EBITDA Margin % Related Terms

Anthera Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Anthera Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthera Pharmaceuticals EBITDA Margin % Chart

Anthera Pharmaceuticals Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -1,097.58 -39,248.97 0.00

Anthera Pharmaceuticals Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANTH vs TIKRF, CAPS, AKAOQ: EBITDA Margin % Comparison

For the Biotechnology subindustry, Anthera Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anthera Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's EBITDA Margin % falls into.


Anthera Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Anthera Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2017 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2017 )/Revenue (A: Dec. 2017 )
=-36.151/0
= %

Anthera Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2018 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2018 )/Revenue (Q: Mar. 2018 )
=-10.81/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Anthera Pharmaceuticals (ANTH) has a EBITDA Margin % of 0.00% as of Mar. 2018. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anthera Pharmaceuticals and its competitors.
Is Anthera Pharmaceuticals' EBITDA Margin % too high?
Anthera Pharmaceuticals' current EBITDA Margin % is 0.00%.
How does Anthera Pharmaceuticals' EBITDA Margin % compare to TIKRF and CAPS?
Anthera Pharmaceuticals' EBITDA Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anthera Pharmaceuticals and its competitors. Anthera Pharmaceuticals's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthera Pharmaceuticals stock overvalued right now?
Anthera Pharmaceuticals (ANTH) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anthera Pharmaceuticals (ANTH), the current EBITDA Margin % is 0.00% as of Mar. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthera Pharmaceuticals Business Description

Address 700 Milam, Suite 1300, Houston, TX, USA, 77002
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.